Enzymatica AB (publ)

Stockholm Stock Exchange ENZY.ST

Enzymatica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2023: -50.96%

Enzymatica AB (publ) Return on Capital Employed (ROCE) is -50.96% for the year ending December 31, 2023, a -10.88% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Enzymatica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -45.96%, a -29.33% change year over year.
Enzymatica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -35.54%, a -215.23% change year over year.
Enzymatica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -11.27%, a 65.72% change year over year.
Enzymatica AB (publ) Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -32.89%, a -35.09% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Stockholm Stock Exchange: ENZY.ST

Enzymatica AB (publ)

CEO	Mr. Claus Egstrand
IPO Date	June 14, 2011
Location	Sweden
Headquarters	Ideon Science Park
Employees	17
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme mouth spray, which prevents common cold and reduces the duration of illness. It also provides enzyme formulations. The company sells mouth spray under the ViruProtect brand in Denmark; STADAProtect brand in Germany; Psysiomer Stop Virus brand in France; and Zerinol Virus Defense brand in Italy. Enzymatica AB was incorporated in 2007 and is headquartered in Lund, Sweden.

Key trends

Past 5 years